Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes

A pooled analysis by performance status of efficacy and safety data from 2 phase III studies

Henri Roché, Pierfranco Conte, Edith A. Perez, Joseph A. Sparano, Binghe Xu, Jacek Jassem, Ronald Peck, Thomas Kelleher, Gabriel N. Hortobagyi

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes often have decreased performance status secondary to extensive tumor involvement. Here, we report the pooled analysis of efficacy and safety data from two similarly designed phase III studies to provide a more precise estimate of benefit of ixabepilone plus capecitabine in MBC patients with Karnofsky's performance status (KPS) 70-80. Across the studies, anthracycline/taxane-pretreated MBC patients were randomized to receive ixabepilone plus capecitabine or capecitabine alone. Individual patient data for KPS 70-80 subset (n = 606) or KPS 90-100 subset (n = 1349) from the two studies were pooled by treatment. Analysis included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and safety. In patients with reduced performance status (KPS 70-80), ixabepilone plus capecitabine was associated with improvements in OS (median: 12.3 vs. 9.5 months; HR, 0.75; P = 0.0015), PFS (median: 4.6 vs. 3.1 months; HR, 0.76; P = 0.0021) and ORR (35 vs. 19%) over capecitabine alone. Corresponding results in patients with high performance status (KPS 90-100) were median OS of 16.7 versus 16.2 months (HR, 0.98; P = 0.8111), median PFS of 6.0 versus 4.4 months (HR, 0.58; P = 0.0009), and ORR of 45 versus 28%. The safety profile of combination therapy was similar between the subgroups. Ixabepilone plus capecitabine appeared to show superior efficacy compared to capecitabine alone in MBC patients previously treated with anthracyclines and taxanes, regardless of performance status, with a possible OS benefit favoring KPS 70-80 patients (ClinicalTrials.gov identifiers: NCT00080301 and NCT00082433).

Original languageEnglish (US)
Pages (from-to)755-765
Number of pages11
JournalBreast Cancer Research and Treatment
Volume125
Issue number3
DOIs
StatePublished - Feb 2011

Fingerprint

Taxoids
Anthracyclines
Karnofsky Performance Status
Breast Neoplasms
Safety
Disease-Free Survival
Survival
Capecitabine
ixabepilone
Therapeutics

Keywords

  • Ixabepilone plus capecitabine
  • Karnofsky's performance status
  • Metastatic breast cancer
  • Overall survival
  • Subset analysis
  • Taxane resistance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes : A pooled analysis by performance status of efficacy and safety data from 2 phase III studies. / Roché, Henri; Conte, Pierfranco; Perez, Edith A.; Sparano, Joseph A.; Xu, Binghe; Jassem, Jacek; Peck, Ronald; Kelleher, Thomas; Hortobagyi, Gabriel N.

In: Breast Cancer Research and Treatment, Vol. 125, No. 3, 02.2011, p. 755-765.

Research output: Contribution to journalArticle

Roché, Henri ; Conte, Pierfranco ; Perez, Edith A. ; Sparano, Joseph A. ; Xu, Binghe ; Jassem, Jacek ; Peck, Ronald ; Kelleher, Thomas ; Hortobagyi, Gabriel N. / Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes : A pooled analysis by performance status of efficacy and safety data from 2 phase III studies. In: Breast Cancer Research and Treatment. 2011 ; Vol. 125, No. 3. pp. 755-765.
@article{0acd738180d2426988a6365616046ce1,
title = "Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: A pooled analysis by performance status of efficacy and safety data from 2 phase III studies",
abstract = "Patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes often have decreased performance status secondary to extensive tumor involvement. Here, we report the pooled analysis of efficacy and safety data from two similarly designed phase III studies to provide a more precise estimate of benefit of ixabepilone plus capecitabine in MBC patients with Karnofsky's performance status (KPS) 70-80. Across the studies, anthracycline/taxane-pretreated MBC patients were randomized to receive ixabepilone plus capecitabine or capecitabine alone. Individual patient data for KPS 70-80 subset (n = 606) or KPS 90-100 subset (n = 1349) from the two studies were pooled by treatment. Analysis included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and safety. In patients with reduced performance status (KPS 70-80), ixabepilone plus capecitabine was associated with improvements in OS (median: 12.3 vs. 9.5 months; HR, 0.75; P = 0.0015), PFS (median: 4.6 vs. 3.1 months; HR, 0.76; P = 0.0021) and ORR (35 vs. 19{\%}) over capecitabine alone. Corresponding results in patients with high performance status (KPS 90-100) were median OS of 16.7 versus 16.2 months (HR, 0.98; P = 0.8111), median PFS of 6.0 versus 4.4 months (HR, 0.58; P = 0.0009), and ORR of 45 versus 28{\%}. The safety profile of combination therapy was similar between the subgroups. Ixabepilone plus capecitabine appeared to show superior efficacy compared to capecitabine alone in MBC patients previously treated with anthracyclines and taxanes, regardless of performance status, with a possible OS benefit favoring KPS 70-80 patients (ClinicalTrials.gov identifiers: NCT00080301 and NCT00082433).",
keywords = "Ixabepilone plus capecitabine, Karnofsky's performance status, Metastatic breast cancer, Overall survival, Subset analysis, Taxane resistance",
author = "Henri Roch{\'e} and Pierfranco Conte and Perez, {Edith A.} and Sparano, {Joseph A.} and Binghe Xu and Jacek Jassem and Ronald Peck and Thomas Kelleher and Hortobagyi, {Gabriel N.}",
year = "2011",
month = "2",
doi = "10.1007/s10549-010-1251-y",
language = "English (US)",
volume = "125",
pages = "755--765",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes

T2 - A pooled analysis by performance status of efficacy and safety data from 2 phase III studies

AU - Roché, Henri

AU - Conte, Pierfranco

AU - Perez, Edith A.

AU - Sparano, Joseph A.

AU - Xu, Binghe

AU - Jassem, Jacek

AU - Peck, Ronald

AU - Kelleher, Thomas

AU - Hortobagyi, Gabriel N.

PY - 2011/2

Y1 - 2011/2

N2 - Patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes often have decreased performance status secondary to extensive tumor involvement. Here, we report the pooled analysis of efficacy and safety data from two similarly designed phase III studies to provide a more precise estimate of benefit of ixabepilone plus capecitabine in MBC patients with Karnofsky's performance status (KPS) 70-80. Across the studies, anthracycline/taxane-pretreated MBC patients were randomized to receive ixabepilone plus capecitabine or capecitabine alone. Individual patient data for KPS 70-80 subset (n = 606) or KPS 90-100 subset (n = 1349) from the two studies were pooled by treatment. Analysis included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and safety. In patients with reduced performance status (KPS 70-80), ixabepilone plus capecitabine was associated with improvements in OS (median: 12.3 vs. 9.5 months; HR, 0.75; P = 0.0015), PFS (median: 4.6 vs. 3.1 months; HR, 0.76; P = 0.0021) and ORR (35 vs. 19%) over capecitabine alone. Corresponding results in patients with high performance status (KPS 90-100) were median OS of 16.7 versus 16.2 months (HR, 0.98; P = 0.8111), median PFS of 6.0 versus 4.4 months (HR, 0.58; P = 0.0009), and ORR of 45 versus 28%. The safety profile of combination therapy was similar between the subgroups. Ixabepilone plus capecitabine appeared to show superior efficacy compared to capecitabine alone in MBC patients previously treated with anthracyclines and taxanes, regardless of performance status, with a possible OS benefit favoring KPS 70-80 patients (ClinicalTrials.gov identifiers: NCT00080301 and NCT00082433).

AB - Patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes often have decreased performance status secondary to extensive tumor involvement. Here, we report the pooled analysis of efficacy and safety data from two similarly designed phase III studies to provide a more precise estimate of benefit of ixabepilone plus capecitabine in MBC patients with Karnofsky's performance status (KPS) 70-80. Across the studies, anthracycline/taxane-pretreated MBC patients were randomized to receive ixabepilone plus capecitabine or capecitabine alone. Individual patient data for KPS 70-80 subset (n = 606) or KPS 90-100 subset (n = 1349) from the two studies were pooled by treatment. Analysis included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and safety. In patients with reduced performance status (KPS 70-80), ixabepilone plus capecitabine was associated with improvements in OS (median: 12.3 vs. 9.5 months; HR, 0.75; P = 0.0015), PFS (median: 4.6 vs. 3.1 months; HR, 0.76; P = 0.0021) and ORR (35 vs. 19%) over capecitabine alone. Corresponding results in patients with high performance status (KPS 90-100) were median OS of 16.7 versus 16.2 months (HR, 0.98; P = 0.8111), median PFS of 6.0 versus 4.4 months (HR, 0.58; P = 0.0009), and ORR of 45 versus 28%. The safety profile of combination therapy was similar between the subgroups. Ixabepilone plus capecitabine appeared to show superior efficacy compared to capecitabine alone in MBC patients previously treated with anthracyclines and taxanes, regardless of performance status, with a possible OS benefit favoring KPS 70-80 patients (ClinicalTrials.gov identifiers: NCT00080301 and NCT00082433).

KW - Ixabepilone plus capecitabine

KW - Karnofsky's performance status

KW - Metastatic breast cancer

KW - Overall survival

KW - Subset analysis

KW - Taxane resistance

UR - http://www.scopus.com/inward/record.url?scp=79251530503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251530503&partnerID=8YFLogxK

U2 - 10.1007/s10549-010-1251-y

DO - 10.1007/s10549-010-1251-y

M3 - Article

VL - 125

SP - 755

EP - 765

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -